Skip to content
Peptigraph home

PT-141 Dosage: Doses Studied, Units and Chart

What doses of PT-141 have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureMelanocortin agonistUpdated
Doses studied
9 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
approximately 2.7 hours (range 1.9-4.0 h)
subcutaneous, in people · FDA label (Vyleesi)
Vial sizes sold
10 mg

Dosing on the FDA label

Quoted from the approved product label. It applies to the approved product used as prescribed, not to compounded or research-chemical versions.

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of PT-141 used in published studies
DoseFrequency and routeStudy typeSource
1.75 mgas needed before sexual activity · subcutaneous · 24 weeksHuman RCTn = 1202Journal of women's health 2022, PMID 35230162
1.75 mgas needed · subcutaneous · 24 weeksHuman RCTn = 1267Obstetrics and gynecology 2019, PMID 31599840
1.75 mgsubcutaneousHuman RCTThe journal of sexual medicine 2019, PMID 31277966
0.75, 1.25 and 1.75 mgsubcutaneousHuman RCTn = 397Journal of hypertension 2017, PMID 27977473
20 mgsingle doses on days 1, 4 and 7, with or without ethanol · intranasalHuman RCTn = 24Clinical therapeutics 2017, PMID 28189361
0.75, 1.25 or 1.75 mgas desired · subcutaneous · 12 weeksHuman RCTn = 327Women's health 2016, PMID 27181790
10 mg45 minutes to 2 hours before sexual stimulation, at least 16 doses/attempts · intranasalHuman RCTn = 342The Journal of urology 2008, PMID 18206919
20 mgsingle dose · intranasalHuman RCTn = 18The journal of sexual medicine 2006, PMID 16839319
0.3 to 10 mg healthy; 4 or 6 mg in ED patientssubcutaneousHuman RCTInternational journal of impotence research 2004, PMID 14999221

Dose to syringe units

For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.

0.25 mg
5 u
0.5 mg
10 u
1 mg
20 u
1.5 mg
30 u
2 mg
40 u
2.5 mg
50 u
Use your own vial and water

Before anyone considers it

  • PT-141 is FDA approved for HSDD (Vyleesi); research-chemical versions are not the approved drug.
  • Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Common questions

How many units is 1 mg of PT-141?

It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 1 mg is 20 units on a U-100 syringe. Use the calculator for other mixes.

Is PT-141 FDA approved?

PT-141 is FDA approved for HSDD (Vyleesi). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

More on PT-141

Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  5. 5Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  6. 6Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
  7. 7Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.Journal of hypertension · 2017PMID 27977473Accessed 2 Oct 2026
  8. 8Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.Clinical therapeutics · 2017PMID 28189361Accessed 2 Oct 2026
  9. 9Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
  10. 10Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
  11. 11An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.The journal of sexual medicine · 2006PMID 16839319Accessed 2 Oct 2026
  12. 12Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026

Found an error? Report a correction.